{"id":57061,"date":"2026-02-13T12:55:11","date_gmt":"2026-02-13T04:55:11","guid":{"rendered":"https:\/\/flcube.com\/?p=57061"},"modified":"2026-02-13T12:55:12","modified_gmt":"2026-02-13T04:55:12","slug":"immunofoco-bio-files-hong-kong-ipo-for-solid-tumor-car-t-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57061","title":{"rendered":"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline"},"content":{"rendered":"\n<p><strong>Shenzhen Immunofoco Biotechnology Co., Ltd.<\/strong>, an <strong>innovative cell therapy developer<\/strong>, has <strong>submitted its IPO application<\/strong> to the <strong>Hong Kong Stock Exchange<\/strong>, seeking to <strong>capitalize on its leadership position in solid tumor CAR-T therapies<\/strong>. The <strong>2020-founded company<\/strong> advances <strong>IMC002<\/strong>, a <strong>potentially best-in-class anti-CLDN18.2 CAR-T<\/strong> in <strong>global Phase III trials<\/strong>\u2014the <strong>second-most advanced solid tumor CAR-T worldwide<\/strong>\u2014alongside <strong>IMC001<\/strong>, a <strong>potentially first-in-class anti-EpCAM CAR-T<\/strong>, and a <strong>proprietary in vitro manufacturing process<\/strong> promising <strong>significant cost advantages<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shenzhen Immunofoco Biotechnology Co., Ltd.<\/td><\/tr><tr><td><strong>Listing Venue<\/strong><\/td><td>Hong Kong Stock Exchange (Main Board)<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>Week of 09\u202fFeb\u202f2026<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2020<\/td><\/tr><tr><td><strong>Sector<\/strong><\/td><td>Innovative cell therapy (CAR-T)<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Solid tumor focus; proprietary manufacturing; cost advantages<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-pipeline\">Clinical Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Target<\/th><th>Stage<\/th><th>Global Positioning<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>IMC002<\/strong><\/td><td><strong>CLDN18.2<\/strong> (gastric, pancreatic, biliary cancers)<\/td><td><strong>Phase III (pivotal)<\/strong><\/td><td><strong>#2 globally<\/strong> among solid tumor CAR-Ts<\/td><td><strong>Best-in-class potential<\/strong>; near-term commercialization<\/td><\/tr><tr><td><strong>IMC001<\/strong><\/td><td><strong>EpCAM<\/strong> (solid tumors)<\/td><td><strong>Phase I\/IIa<\/strong><\/td><td><strong>First-in-class<\/strong><\/td><td>Novel target; broad applicability across epithelial cancers<\/td><\/tr><tr><td><strong>Manufacturing Platform<\/strong><\/td><td><strong>In vitro CAR-T production<\/strong><\/td><td>Proprietary<\/td><td><strong>Cost advantage<\/strong> vs. autologous processes<\/td><td><strong>Scalability<\/strong>; <strong>reduced COGS<\/strong>; <strong>commercial viability<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-biology-amp-market-context\">Target Biology &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Target<\/th><th>Expression Profile<\/th><th>Addressable Market<\/th><\/tr><\/thead><tbody><tr><td><strong>CLDN18.2<\/strong><\/td><td><strong>Gastric cancer (70%+), pancreatic cancer (50%+), biliary tract cancer (60%+)<\/strong><\/td><td><strong>&gt;500,000 new cases annually in China<\/strong>; <strong>high unmet need<\/strong> in <strong>CLDN18.2-positive solid tumors<\/strong><\/td><\/tr><tr><td><strong>EpCAM<\/strong><\/td><td><strong>Epithelial cancers<\/strong> (breast, lung, colorectal, ovarian)<\/td><td><strong>Broad solid tumor applicability<\/strong>; <strong>potential &#8220;pan-cancer&#8221; CAR-T approach<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Solid Tumor CAR-T Challenge:<\/strong> <strong>Tumor microenvironment immunosuppression<\/strong>, <strong>antigen heterogeneity<\/strong>, and <strong>on-target, off-tumor toxicity<\/strong> have limited CAR-T success in solid tumors vs. hematologic malignancies; <strong>Immunofoco&#8217;s clinical progress<\/strong> demonstrates <strong>differentiated technology platform<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-manufacturing-innovation\">Manufacturing Innovation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Immunofoco In Vitro Process<\/th><th>Traditional Autologous CAR-T<\/th><th>Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Cell Source<\/strong><\/td><td><strong>Allogeneic\/off-the-shelf<\/strong> or <strong>optimized autologous<\/strong><\/td><td>Patient-derived T-cells<\/td><td><strong>Reduced manufacturing variability<\/strong>; <strong>immediate availability<\/strong><\/td><\/tr><tr><td><strong>Production Scale<\/strong><\/td><td><strong>Scalable bioreactor culture<\/strong><\/td><td>Individual patient batches<\/td><td><strong>Cost reduction<\/strong>; <strong>commercial scalability<\/strong><\/td><\/tr><tr><td><strong>Quality Control<\/strong><\/td><td><strong>Standardized, GMP-compliant<\/strong><\/td><td>Patient-specific testing<\/td><td><strong>Regulatory efficiency<\/strong>; <strong>batch consistency<\/strong><\/td><\/tr><tr><td><strong>Cost Structure<\/strong><\/td><td><strong>Significantly lower COGS<\/strong><\/td><td>High personalized manufacturing costs<\/td><td><strong>Pricing flexibility<\/strong>; <strong>market access advantage<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-competitive-landscape\">Strategic Positioning &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>China CAR-T Ecosystem<\/strong><\/td><td><strong>Fosun Kite, JW Therapeutics, CARsgen<\/strong> lead in <strong>hematologic CAR-T<\/strong>; <strong>Immunofoco solid tumor focus<\/strong> creates <strong>differentiated positioning<\/strong><\/td><\/tr><tr><td><strong>Global Solid Tumor CAR-T Race<\/strong><\/td><td><strong>Poseida (BCMA), Tmunity (PSMA), PACT Pharma (neoantigen)<\/strong> in early stages; <strong>IMC002 Phase III<\/strong> positions <strong>Immunofoco as global leader<\/strong><\/td><\/tr><tr><td><strong>CLDN18.2 Competition<\/strong><\/td><td><strong>Zolbetuximab (Astellas)<\/strong> approved 2024 as <strong>naked antibody<\/strong>; <strong>CAR-T offers superior potency<\/strong> and <strong>potential for curative intent<\/strong><\/td><\/tr><tr><td><strong>IPO Timing Rationale<\/strong><\/td><td><strong>Hong Kong biotech window reopening<\/strong>; <strong>Phase III data catalyst<\/strong> anticipated 2026-2027; <strong>manufacturing scale-up capital requirements<\/strong><\/td><\/tr><tr><td><strong>Ex-China Potential<\/strong><\/td><td><strong>Global Phase III design<\/strong> supports <strong>US\/EU regulatory pathway<\/strong>; <strong>partnership or self-commercialization<\/strong> options<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Immunofoco Biotechnology&#8217;s Hong Kong IPO completion, IMC002 Phase III clinical outcomes, and solid tumor CAR-T commercialization potential. Actual results may differ due to solid tumor CAR-T efficacy and safety challenges, manufacturing scale-up execution, and competitive dynamics with CLDN18.2-targeted therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26021300027_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26021300027_c.\"><\/object><a id=\"wp-block-file--media-c72793b2-0949-4cfb-8a20-6845382f3776\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26021300027_c.pdf\">sehk26021300027_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26021300027_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c72793b2-0949-4cfb-8a20-6845382f3776\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shenzhen Immunofoco Biotechnology Co., Ltd., an innovative cell therapy developer, has submitted its IPO application&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57063,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2253,72],"class_list":["post-57061","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-immunofoco","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen Immunofoco Biotechnology Co., Ltd., an innovative cell therapy developer, has submitted its IPO application to the Hong Kong Stock Exchange, seeking to capitalize on its leadership position in solid tumor CAR-T therapies. The 2020-founded company advances IMC002, a potentially best-in-class anti-CLDN18.2 CAR-T in global Phase III trials\u2014the second-most advanced solid tumor CAR-T worldwide\u2014alongside IMC001, a potentially first-in-class anti-EpCAM CAR-T, and a proprietary in vitro manufacturing process promising significant cost advantages.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57061\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline\" \/>\n<meta property=\"og:description\" content=\"Shenzhen Immunofoco Biotechnology Co., Ltd., an innovative cell therapy developer, has submitted its IPO application to the Hong Kong Stock Exchange, seeking to capitalize on its leadership position in solid tumor CAR-T therapies. The 2020-founded company advances IMC002, a potentially best-in-class anti-CLDN18.2 CAR-T in global Phase III trials\u2014the second-most advanced solid tumor CAR-T worldwide\u2014alongside IMC001, a potentially first-in-class anti-EpCAM CAR-T, and a proprietary in vitro manufacturing process promising significant cost advantages.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57061\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T04:55:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-13T04:55:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57061#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57061\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline\",\"datePublished\":\"2026-02-13T04:55:11+00:00\",\"dateModified\":\"2026-02-13T04:55:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57061\"},\"wordCount\":477,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57061#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1302.webp\",\"keywords\":[\"Immunofoco\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57061#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57061\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57061\",\"name\":\"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57061#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57061#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1302.webp\",\"datePublished\":\"2026-02-13T04:55:11+00:00\",\"dateModified\":\"2026-02-13T04:55:12+00:00\",\"description\":\"Shenzhen Immunofoco Biotechnology Co., Ltd., an innovative cell therapy developer, has submitted its IPO application to the Hong Kong Stock Exchange, seeking to capitalize on its leadership position in solid tumor CAR-T therapies. The 2020-founded company advances IMC002, a potentially best-in-class anti-CLDN18.2 CAR-T in global Phase III trials\u2014the second-most advanced solid tumor CAR-T worldwide\u2014alongside IMC001, a potentially first-in-class anti-EpCAM CAR-T, and a proprietary in vitro manufacturing process promising significant cost advantages.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57061#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57061\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57061#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1302.webp\",\"width\":1080,\"height\":608,\"caption\":\"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57061#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Shenzhen Immunofoco Biotechnology Co., Ltd., an innovative cell therapy developer, has submitted its IPO application to the Hong Kong Stock Exchange, seeking to capitalize on its leadership position in solid tumor CAR-T therapies. The 2020-founded company advances IMC002, a potentially best-in-class anti-CLDN18.2 CAR-T in global Phase III trials\u2014the second-most advanced solid tumor CAR-T worldwide\u2014alongside IMC001, a potentially first-in-class anti-EpCAM CAR-T, and a proprietary in vitro manufacturing process promising significant cost advantages.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57061","og_locale":"en_US","og_type":"article","og_title":"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline","og_description":"Shenzhen Immunofoco Biotechnology Co., Ltd., an innovative cell therapy developer, has submitted its IPO application to the Hong Kong Stock Exchange, seeking to capitalize on its leadership position in solid tumor CAR-T therapies. The 2020-founded company advances IMC002, a potentially best-in-class anti-CLDN18.2 CAR-T in global Phase III trials\u2014the second-most advanced solid tumor CAR-T worldwide\u2014alongside IMC001, a potentially first-in-class anti-EpCAM CAR-T, and a proprietary in vitro manufacturing process promising significant cost advantages.","og_url":"https:\/\/flcube.com\/?p=57061","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-13T04:55:11+00:00","article_modified_time":"2026-02-13T04:55:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57061#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57061"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline","datePublished":"2026-02-13T04:55:11+00:00","dateModified":"2026-02-13T04:55:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57061"},"wordCount":477,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57061#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1302.webp","keywords":["Immunofoco","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57061#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57061","url":"https:\/\/flcube.com\/?p=57061","name":"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57061#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57061#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1302.webp","datePublished":"2026-02-13T04:55:11+00:00","dateModified":"2026-02-13T04:55:12+00:00","description":"Shenzhen Immunofoco Biotechnology Co., Ltd., an innovative cell therapy developer, has submitted its IPO application to the Hong Kong Stock Exchange, seeking to capitalize on its leadership position in solid tumor CAR-T therapies. The 2020-founded company advances IMC002, a potentially best-in-class anti-CLDN18.2 CAR-T in global Phase III trials\u2014the second-most advanced solid tumor CAR-T worldwide\u2014alongside IMC001, a potentially first-in-class anti-EpCAM CAR-T, and a proprietary in vitro manufacturing process promising significant cost advantages.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57061#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57061"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57061#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1302.webp","width":1080,"height":608,"caption":"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57061#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57061"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57061\/revisions"}],"predecessor-version":[{"id":57064,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57061\/revisions\/57064"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57063"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}